Hoth Therapeutics Amends Q3 2024 Financial Filing

Ticker: HOTH · Form: 8-K · Filed: Dec 2, 2024 · CIK: 1711786

Hoth Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyHoth Therapeutics, Inc. (HOTH)
Form Type8-K
Filed DateDec 2, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: amendment, financial-reporting, 10-Q

Related Tickers: HOTH

TL;DR

HOTH amended its Q3 2024 10-Q filing - check the financials.

AI Summary

On December 2, 2024, Hoth Therapeutics, Inc. filed an 8-K report detailing an amendment to its previously filed Form 10-Q for the quarterly period ended September 30, 2024. This amendment primarily concerns the financial statements and related disclosures within that 10-Q filing.

Why It Matters

This filing indicates a correction or update to Hoth Therapeutics' financial reporting for the third quarter of 2024, which could impact investor understanding of the company's financial position.

Risk Assessment

Risk Level: low — This is a routine amendment to a previous financial filing and does not appear to introduce new material risks.

Key Players & Entities

  • Hoth Therapeutics, Inc. (company) — Registrant
  • December 2, 2024 (date) — Date of Report
  • September 30, 2024 (date) — Quarterly period end for amended filing

FAQ

What specific items were amended in the Form 10-Q for the period ended September 30, 2024?

The filing states that the amendment is to correct and update the financial statements and related disclosures previously filed in the Form 10-Q for the quarterly period ended September 30, 2024.

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report an amendment to Hoth Therapeutics, Inc.'s previously filed Form 10-Q for the quarterly period ended September 30, 2024.

When was the original Form 10-Q filed that is being amended?

The filing does not explicitly state the original filing date of the Form 10-Q being amended, only that the amendment is being reported on December 2, 2024.

What is Hoth Therapeutics, Inc.'s state of incorporation?

Hoth Therapeutics, Inc. is incorporated in Nevada.

What is the principal executive office address for Hoth Therapeutics, Inc.?

The principal executive offices are located at 590 Madison Ave, 21st Floor, New York, New York 10022.

Filing Stats: 534 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-12-02 16:15:43

Key Financial Figures

  • $0.0001 — nge on which registered Common stock, $0.0001 par value HOTH The Nasdaq Stock Mar

Filing Documents

01 Other Events

Item 8.01 Other Events. Hoth Therapeutics, Inc. (the "Company") has prepared presentation materials (the "Presentation Materials") that management intends to use from time to time on and after December 2, 2024, in presentations about the Company's operations and performance. The Presentation Materials are filed as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in the Presentation Materials is summary information that should be considered within the context of the Company's filings with the Securities and Exchange Commission and other public announcements that the Company may make by press release or otherwise from time to time. The Presentation Materials speak as of the date of this Current Report on Form 8-K. While the Company may elect to update the Presentation Materials in the future or reflect events and circumstances occurring or existing after the date of this Current Report on Form 8-K, the Company specifically disclaims any obligation to do so.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Presentation Materials 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 2, 2024 Hoth Therapeutics, Inc. /s/ Robb Knie Robb Knie Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.